No benefit seen for adjuvant oxaliplatin in stage II colon CA

August 21, 2012
No benefit seen for adjuvant oxaliplatin in stage II colon CA
For elderly patients with colon cancer or those with stage II disease, the addition of oxaliplatin to fluorouracil with leucovorin does not seem to offer any survival benefit, according to a study published online Aug. 20 in the Journal of Clinical Oncology.

(HealthDay) -- For elderly patients with colon cancer or those with stage II disease, the addition of oxaliplatin to fluorouracil with leucovorin (FL) does not seem to offer any survival benefit, according to a study published online Aug. 20 in the Journal of Clinical Oncology.

Christophe Tournigand, M.D., Ph.D., from the Hôpital Saint-Antoine in Paris, and colleagues conducted subgroup analyses of stage II and elderly patients with colon cancer, who were randomly assigned to FL with or without (FOLFOX4).

The researchers found that 889 patients had stage II disease, including 569 high-risk and 330 low-risk patients, and 315 patients were aged 70 to 75 years. Comparing FOLFOX4 with FL, the hazard ratios (HRs) for stage II patients were not significant for disease-free survival (DFS) or overall survival (OS), and no interaction was noted between treatment and age or stage. There was no benefit seen for low-risk stage II patients. For high-risk stage II patients and for elderly patients, the HRs comparing FOLFOX4 with FL were not significant for DFS or OS.

"The addition of oxaliplatin to infusional fluorouracil/leucovorin has not been shown to be beneficial in low-risk or high-risk stage II patients or for patients between 70 and 75 years," the authors write. "The identification of a patient population for which adjuvant therapy is necessary, safe, and effective continues to be challenging, especially for high-risk stage II patients and for elderly patients."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Study showed oxaliplatin improved colon cancer patient survival

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Study showed oxaliplatin improved colon cancer patient survival

January 20, 2012
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published ...

Nonoperative approach feasible in advanced colon cancer

August 9, 2012
(HealthDay) -- Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy ...

High survival with surgery in low-risk neuroblastoma

April 25, 2012
(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Recommended for you

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.